Publications

Publications (2005-2010)

 

Clinical Proteomics and Bioinformatics:

Vafadar-Isfahani B, Laversin S, Coveney C, Ahmad M, Miles M, Ball G, Schalkwyk G, Rees R,Matharoo-Ball B Serum.  Biomarkers which correlate with failure to respond to immunotherapy and tumour progression in amurine colorectal cancer model. Proteomics Clinical Applications.  2010; 4 (8-9): 682-696.

Lancashire LJ, Powe DG, Reis-Filho JS, Rakha E, Lemetre C, Weigelt B, Abdel-Fatah TM, Green AR,Mukta R, Blamey R, Paish EC, Rees RC, Ellis IO, Ball GR. A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks. Breast Cancer Res Treat. 2010; 120 (1): 83-93.

Blamey RW, Hornmark-Stenstama B, Ball G, Blichert-Toft, M, Cataliotti L, Fourquet A, Geed J, Holli K, Jakesz R, Kerin M, Mansel R, Nicholson R, Pienkowski T, Pinder S, Sundquist M, Van de Vijver M, Ellis I. A. European database for 16,944 cases of breast cancer. Eur J Cancer 2010; 46(1):56-71.

Zhang H, Rakha EA, Ball GR, Spiteri I, Aleskandarany M, Paish EC, Powe DG,Macmillan RD, Caldas C, Ellis IO, Green AR. The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer. Breast Cancer Res Treat.2010; 121 (1) 41- 51.

Habashy HO, Powe DG, Rakha EA, Ball G, Macmillan D, Green AR, Ellis IO. The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype. Breast Cancer Res Treat. 2010; ;120 (3): 603-12.

Khan RN,Matharoo-Ball B, Shaw R. Antioxidant enzyme expression, lipid peroxidation and protein oxidation in human myometrium with parturition. Reprod Sci. 2010; 17(1): 78-84.

Lowery AJ,Miller N, Devaney A,McNeill R, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ. MicroRNA signatures predict estrogen receptor, progesterone receptor and HER2 / neu receptor status in breast cancer. Breast Cancer Res.2009; 11(3): R27.

Kay RG, Barton C, Velloso CP, Brown PA, Bartlett C, Blazevich AJ, Godfrey RJ, Goldspink G, Rees R, Ball GR, Cowan DA, Harridge SD, Roberts J, Teale P, Creaser C. High throughput ultra-high-performance liquid chromatography / tandemmass spectrometry quantitation of insulin-like growth factor-I and leucine-rich-a-2-glycoprotein in serum as biomarkers of recombinant human growth hormone administration. Rapid CommunMass Spectrom. 2009; 23:1-10.

Tumour Immunology and Molecular Genetics:

Linley AJ,Miles AK, Al-FawazM, Lu C,McArdle SEB, Rees RC, MathieuMG. Non-X-linked cancer/testis antigens: identification, expression profile and immunogenicity. Curr Trends Immunol. 2010; 10: 49-59.

Mathieu MG, Linley AJ, Reeder SP, Badoual C, Tartour E, Rees RC,McArdle SE. HAGE, a cancer/testis antigen expressed at the protein level in a variety of cancers. Cancer Immun. 2010; 11;10:2.

ZhangW, Caspell R, Karulin AY, AhmadM, Haicheur N, AbdelsalamA, Johannesen K, Vignard V, Dudzik P, Georgakopoulou K,Mihaylova A, Silina K, Aptsiauri N, Adams V, Lehmann PV,McArdle S. ELISPOT assays provide reproducible results among different laboratories for T-cell immunemonitoring--even in hands of ELISPOT-inexperienced investigators. J Immunotoxicol. 2009; 6(4):227-34.

Riley CL, Mathieu MG, Clark RE,McArdle SE, Rees RC. Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable? Cancer Immunol Immunother 2009; 58(9):1489-99.

Mathieu M,Miles AK, Li, G,McArdle, SE, Rees RC. Cancer/Testis antigens for therapeutic use. J BUON.2009; 14: Suppl 1: S97-102.

McArdle SE, Rees RC. Tumour Immunology: new perspectives. Cancer Res.2009; 69(18): 7157-7159. CONFERENCE REPORT

Kapoor KN, Barry DT, Rees RC, Dodi IA, McArdle SE, Creaser CS, Bonner PL. Estimation of peptide concentration by a modified bicinchoninic acid assay. Anal Biochem. 2009; 393(1): 138-140.